UCB, Teva, Novartis, Pfizer and TransCelerate Biopharma win industry recognition at the eyeforpharma Philadelphia Awards 2016

eyeforpharma 2 - 3 May 2016, Philadelphia, USA.
The 2016 eyeforpharma Philadelphia Awards saw 22 finalists, with representation from every top 20 pharma, showcase the breadth of innovation within the industry. Submissions displayed cutting-edge application of new strategies for old problems.

Teva won the Most Valuable HCP or Healthcare Initiative with their foray into Artificial Intelligence. Teva presented "ASK Claire", an Intelligent Virtual Health Assistant that engages Multiple sclerosis (MS) patients on the web and in an app.

UCB picked up the Most Valuable Patient Initiative or Service Award with their Report Cards submission. The team presented an intriguing approach to create new incentives for decision makers to prioritise innovative therapies for Epilepsy Patients, by creating transparency into current care outcomes.

Individual leaders were also recognized for their refusal to accept the status quo, showing the way for the industry to progress. Chrisi Shaw, the, U.S. Country Head and President of Novartis picked up the Lifetime Achievement Award for her leadership on gender equality and contributions to patient-centricity throughout the pharma lifecycle.

Pfizer's Dennis Freire was awarded for his contributions towards patient-centric clinical trials with the Customer Innovator Award. Through a collaboration with ICON Firecrest collaboration, Freire oversaw a radical re-think of the onerous procedures facing patient registrants for clinical trials.

The groundbreaking consortium of top 20 pharma TransCelerate was also recognized with the Most Valuable Pharma Collaboration award for the work they've achieved in unlocking innovation that benefits everyone in pharma. Through shared research partnerships and close regulatory coordination, they are redefining the boundaries of what is possible in cross-industry collaboration on issues of shared commercial, and patient-centric interest.

The awards reflect eyeforpharma's mission to evangelize the need for pharma to change its focus from selling products, to seeing the powerful opportunity that pharma has to impact and improve the lives of patients. The winning projects were selected from hundreds of initiatives submitted from teams across the global, and determined by a judging panel of senior industry experts, and patient advocates.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...